National Anti-Doping Laboratory, No. 1 Anding Road, ChaoYang District, 100029 Beijing, People's Republic of China.
School of Mathematics, Sun Yat-sen University, No. 135 Xingang Xi Road, HaiZhu District, 510275 Guangzhou, People's Republic of China.
Anal Methods. 2021 Dec 16;13(48):5838-5850. doi: 10.1039/d1ay01677f.
This study described a reliable analytical method, which combines solid-phase extraction (SPE) with liquid chromatography-high resolution mass spectrometry (LC-HRMS) employing the parallel reaction monitoring (PRM) mode, for screening 41 small peptides and 3 non-peptide growth hormone secretagogues in human urine. Additionally 36 small peptides and 3 non-peptide growth hormone secretagogues were also confirmed in the same way. For the whole screening procedure, the PRM mode was applied to the HRMS detection of small peptides, which reduces the background noise from matrix compounds to a large extent and thus improves the selectivity and reliability of the peptide analytes. Meanwhile, competent chromatographic separation was achieved within a total runtime of 14 minutes, indicating an improvement in the detection efficiency. Moreover, the PRM mode could also be applied to the confirmation procedure due to its strong identification power with a low risk of generating false positives or negatives and good selectivity. Validation was performed according to the relevant World Anti-Doping Agency (WADA) criteria, including selectivity and reliability, limit of detection (LOD), limit of identification (LOI), recovery, extraction stability and carryover. The LODs of the peptide analytes ranged between 0.20 ng mL and 0.92 ng mL in urine, while their LOIs ranged between 0.20 ng mL and 2.00 ng mL, which met the corresponding Minimum Required Performance Levels (MRPLs) as defined by WADA. The developed method furnished the rapid and sensitive detection of small peptides in urine for more than 5000 samples with no false-positive or false-negative, indicating that it is an eligible method for doping control analysis.
本研究描述了一种可靠的分析方法,该方法结合固相萃取(SPE)和液相色谱-高分辨质谱(LC-HRMS),采用平行反应监测(PRM)模式,用于筛选人尿中的 41 种小肽和 3 种非肽生长激素促分泌素。同样的方法也确认了 36 种小肽和 3 种非肽生长激素促分泌素。对于整个筛选过程,PRM 模式应用于 HRMS 检测小肽,这大大降低了基质化合物的背景噪声,从而提高了肽分析物的选择性和可靠性。同时,在总运行时间为 14 分钟内实现了有效的色谱分离,表明检测效率得到了提高。此外,由于 PRM 模式具有较强的鉴定能力,假阳性或假阴性的风险低,选择性好,也可应用于确证程序。验证按照世界反兴奋剂机构(WADA)的相关标准进行,包括选择性和可靠性、检测限(LOD)、确证限(LOI)、回收率、提取稳定性和交叉污染。肽分析物在尿液中的 LOD 范围为 0.20ng/mL 至 0.92ng/mL,LOI 范围为 0.20ng/mL 至 2.00ng/mL,符合 WADA 定义的最低性能要求(MRPL)。所建立的方法在 5000 多个样品中进行了快速、灵敏的小肽检测,没有假阳性或假阴性,表明它是一种适合兴奋剂控制分析的方法。